SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Discussion centers on Compounds reported institutional-market push, leadership changes, and planned V4 and tokenized-asset development. Traders are divided between buying the weakness on expectations of a turnaround and frustration that COMP continues to lag other crypto assets.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, unexplained XCN price spike and volatile swings are driving attention, with traders highlighting a large candle and a brief pump. Some are buying dips and expecting a rebound, while others call the move a pump-and-dump and question whether gains will hold.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Fresh Phase 3 biliary-tract cancer results for ivonescimab showing a survival benefit over standard treatment are driving attention, alongside anticipation of the separate November 14 FDA decision for the drug in EGFR-mutated lung cancer. Traders are encouraged by the data but debate how much weight to give China-based interim results and whether the positive news will overcome recent share-price weakness.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Nateras repeated 52-week highs and strong momentum are drawing attention, with bulls pointing to demand for its genetic and oncology diagnostics, including MRD testing, while others caution that the run looks overextended. Billing-settlement updates are also circulating, but some traders view them as secondary to test-volume growth.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

QNTs sharp rally and subsequent volatility are being tied by traders to Quants reported role in The Clearing Houses tokenized-deposit initiative and broader hopes for institutional adoption. Bulls see banking tokenization and limited supply as potential drivers, while skeptics question whether the software deal creates direct demand for QNT tokens.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs volatile price action is driving debate, with bullish traders anticipating a rebound and pointing to the planned CashVM/Layla upgrade, while skeptics question its utility and warn of further declines. Discussion also references CME futures access and a Grayscale filing as possible support, but views on BCHs momentum remain divided.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Cantons institutional tokenization pushespecially discussion of DTCCs plans and major financial firms joining the networkis drawing attention to CC. Traders are bullish on adoption and real-world-asset activity, while others question whether network growth will benefit the token given ongoing issuance and unlocks.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for its prolonged, range-bound trading, with traders repeatedly discussing consolidation and nearby support and resistance. Some holders are accumulating and anticipating a breakout, while others expect further weakness and question the tokens utility.

Select Sector SPDR Trust (The) - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

Utilities defensive-sector strength and sensitivity to Treasury yields dominate discussion, with traders describing rotation into XLU as investors seek shelter from market and macro uncertainty. Some also point to AI-driven electricity demand as longer-term support, while others caution that utilities remain vulnerable to shifts in rate expectations.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins pullback is driving discussion, with many traders treating it as a temporary dip to buy and expecting a recovery, while others warn of further weakness and possible selling by ETF holders. The debate reflects uncertainty over whether the decline is a routine shakeout or a deeper setback for the crypto rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVO not to brag but every month I’m buying 1000 more shares at this price 😂  that’s how confident I’m. If this was 2024 or 2025. I completely agreed with the bear thesis. Ever since oral wegovy came out and the numbers keep blowing out expectations, plus the two quarters of raising guidances. It’s a no brainer what next quarter will be.

tthe tthe

Chesney Buitendijk

azkaazka

spliffmeister

Paul Howard

Veiko Valkiainen

Krish

Mark

chiku

Anoj Anandamageswaran

StockTwits for iOS

Novo Nordisk A/S

 not to brag but every month I’m buying 1000 more shares at this price 😂  that’s how confident I’m. If this was 2024 or 2025. I completely agreed with the bear thesis. Ever since oral wegovy came out and the numbers keep blowing out expectations, plus the two quarters of raising guidances. It’s a no brainer what next quarter will be.

Pseudominds

@Pseudominds damn at how many shares are you atm?

@Pseudominds Nice. I am also about to add. At these levels its nobrainer and in 2yrs from now will thanks my younger self.

StockTwits Web

 Nice. I am also about to add. At these levels its nobrainer and in 2yrs from now will thanks my younger self.

@azkaazka patent cliff is 2032, snac and bunch of other patents aren’t expire until 2038 etc. the manufacture capacity moat is very difficult to produce for other competitors. I’m betting Lily and novo will still take about 70% of the entire glp market by 2030. And that’s 1 billion patients. Right now it’s 50 million globally (5%). If it reaches to $150 million patient that’s still only 15% but explosion in market share.

 patent cliff is 2032, snac and bunch of other patents aren’t expire until 2038 etc. the manufacture capacity moat is very difficult to produce for other competitors. I’m betting Lily and novo will still take about 70% of the entire glp market by 2030. And that’s 1 billion patients. Right now it’s 50 million globally (5%). If it reaches to $150 million patient that’s still only 15% but explosion in market share.